Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKDBFL)

Drug Name

HBR-985 Drug Info

Synonyms

Glicondamide; 52994-25-9; UNII-876SH4764F; C18H20ClN3O5S; 876SH4764F; 1-[[p-[2-(5-chloro-o-anisamido)ethyl]phenyl]sulfonyl]-3-methylurea; Glicondamide [INN]; 1-((p-(2-(5-Chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-methylurea; AC1Q3LT7; CHEMBL12806; AC1L562G; SCHEMBL1818252; CTK4J6836; DTXSID10201026; ZINC537790; HB-985; AKOS030573774; ACM52994259; W0037; 5-chloro-2-methoxy-N-[2-[4-(methylcarbamoylsulfamoyl)phenyl]ethyl]benzamide

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 219108
CAS Number: CAS 52994-25-9
TTD Drug ID: DMKDBFL
VARIDT Drug ID: DR00830

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting ATP-binding cassette transporter C8 (ABCC8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glibenclamide	DM8JXPZ	Diabetic complication	5A2Y	Approved	[2]
Tolbutamide	DM02AWV	Advanced cancer	2A00-2F9Z	Approved	[3]
Repaglinide	DM5SXUV	Diabetic complication	5A2Y	Approved	[4]
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[5]
Acetohexamide	DMR6N7H	Diabetic complication	5A2Y	Approved	[6]
Gliclazide	DMN6QO5	Diabetic complication	5A2Y	Approved	[7]
NN-414	DMRJEXM	Type-1 diabetes	5A10	Phase 1	[8]
NS-11757	DM98VMZ	Atrial fibrillation	BC81.3	Investigative	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
ATP-binding cassette transporter C8 (ABCC8)	TTP835K	ABCC8_HUMAN	Inhibitor	[1]
Inward rectifier potassium channel Kir6.2 (KCNJ11)	TT329V4	KCJ11_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Cardioselective K(ATP) channel blockers derived from a new series of m-anisamidoethylbenzenesulfonylthioureas. J Med Chem. 2001 Mar 29;44(7):1085-98.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3	Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. J Clin Invest. 2009 Jan;119(1):80-90.
4	Metformin/Repaglinide (PrandiMet) for type 2 diabetes. Med Lett Drugs Ther. 2009 Jun 1;51(1313):41-3.
5	Mechanism of disopyramide-induced hypoglycaemia in a patient with Type 2 diabetes. Diabet Med. 2009 Jan;26(1):76-8.
6	Diabetes and insulin secretion: the ATP-sensitive K+ channel (K ATP) connection.Diabetes.2005 Nov;54(11):3065-72.
7	Structural basis for the interference between nicorandil and sulfonylurea action. Diabetes. 2001 Oct;50(10):2253-9.
8	Attenuation of hyperinsulinemia by NN414, a SUR1/Kir6.2 selective K-adenosine triphosphate channel opener, improves glucose tolerance and lipid profile in obese Zucker rats.Metabolism.2004 Apr;53(4):441-7.
9	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2944).